Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774811 | 0.81 | TP53 (0.32) | TSHR | |
| SCHEMBL722644 | 0.78 | LMNA (0.35) | LMNABLM | |
| SCHEMBL722643 | 0.78 | LMNA (0.35) | LMNABLM | |
| SCHEMBL14525328 | 0.78 | LMNA (0.35) | LMNABLM | |
| SCHEMBL29343521 | 0.77 | FFAR1 (0.37) | TSHRADRA1A | |
| SCHEMBL11567410 | 0.76 | MEN1 (0.32) | CYP2C9LMNADRD3CYP2D6CYP2C19 | |
| SCHEMBL18901903 | 0.76 | MEN1 (0.32) | CYP2C9LMNADRD3CYP2D6CYP2C19 | |
| SCHEMBL14198755 | 0.76 | — | — | |
| SCHEMBL1977622 | 0.74 | — | — | |
| SCHEMBL12740557 | 0.72 | MME (0.35) | PTGS2PTGS1LMNACXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197156-A1 | NEW ULTRAHIGH EFFICIENCY, SUPERFICIALLY POROUS PARTICLE (SPP) CHIRAL PHASES FOR LIQUID CHROMATOGRAPHY | AZYP, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| EP-1366012-A4 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002064094-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PTGS2 506/4885PTGS1 510/4885CYP2C9 1677/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | PTGS2 219/4885PTGS1 170/4885CYP2C9 2041/4885 |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PTGS2 702/4885PTGS1 740/4885CYP2C9 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.